Secnidazole - Generic Drug Details

What are the generic drug sources for secnidazole and what is the scope of freedom to operate?

Secnidazole is the generic ingredient in one branded drug marketed by Evofem Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Secnidazole has sixteen patent family members in five countries.

There are two drug master file entries for secnidazole. One supplier is listed for this compound.

Summary for secnidazole

International Patents:	16
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for secnidazole
What excipients (inactive ingredients) are in secnidazole?	secnidazole excipients list
DailyMed Link:	secnidazole at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for secnidazole

Constraining patent/regulatory exclusivity:

10,849,884

Dosage:

GRANULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for secnidazole

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Segal Trials Healthcare Clinical Data, Inc	PHASE4
Tulane University	PHASE4
Louisiana State University Health Sciences Center in New Orleans	PHASE4

See all secnidazole clinical trials

Pharmacology for secnidazole

Drug Class

Nitroimidazole Antimicrobial

Anatomical Therapeutic Chemical (ATC) Classes for secnidazole

P01AB	Nitroimidazole derivatives
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
P01	ANTIPROTOZOALS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for secnidazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,602,522		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	12,280,037
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,684,607		Y
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,020,377		Y

International Patents for secnidazole

Country	Patent Number	Title	Estimated Expiration
South Korea	20170052626	세균질증 치료에 사용하기 위한 세크니다졸 (SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS)
Japan	6637624
Canada	3046521	SECNIDAZOLE A UTILISER DANS LE TRAITEMENT DE VAGINOSE BACTERIENNE (SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS)
South Korea	20170052626	세균질증 치료에 사용하기 위한 세크니다졸 (SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS)
South Korea	20170052626

Secnidazole Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Secnidazole?

Secnidazole, an antiprotozoal and antibacterial agent primarily used to treat bacterial vaginosis (BV) and other protozoal infections, is positioning itself within a growing segment of the global anti-infective drugs market. Several factors influence its market trajectory, including therapeutic need, competitive landscape, regulatory environment, and manufacturing capacity.

Therapeutic Demand and Clinical Use

Secnidazole's approval for BV, a common condition affecting women globally, drives consistent demand. BV prevalence varies from 15% to 50% among women of reproductive age, with an estimated 30% prevalence in the United States (Centers for Disease Control and Prevention, 2021). The drug's advantage lies in its single oral dose regimen, improving patient compliance compared to longer courses of antibiotics like metronidazole or tinidazole.

Other potential applications are being explored, notably in treating trichomoniasis and certain parasitic infections. However, current demand remains concentrated on BV, which accounts for approximately 10 million prescriptions annually in the U.S. alone.

Competitive and Regulatory Landscape

Secnidazole's market shares are limited by the presence of established drugs such as metronidazole and tinidazole. Its market entry was facilitated by the FDA’s approval of Secnuva in 2017 (FDA, 2017), which authorized a single-dose regimen, a key differentiator.

Competitors include generic formulations of metronidazole, which dominate due to low costs and long market presence. A significant challenge for secnidazole lies in establishing its clinical advantage over these generics. Changes in regulatory policies, such as approval of combination therapies or new formulations, could influence its market share.

Manufacturing and Supply Chain Factors

The scalability of manufacturing is critical. Secnidazole is synthesized via established chemical processes, with major pharmaceutical companies capable of producing it at scale. Supply chain disruptions, however, can impact drug availability, particularly if raw material sourcing becomes constrained or regulatory hurdles increase.

Market Penetration and Adoption

The drug’s adoption depends heavily on physician preference and reimbursement policies. Single-dose regimens are favored for reducing treatment failure and recurrence; thus, secnidazole has a competitive edge. However, patient awareness and clinician familiarity influence prescribing behaviors.

Future Outlook

Market growth is contingent on expanding indications, optimizing pricing strategies, and overcoming generic competition. The global anti-infective market is expected to grow at a compound annual growth rate (CAGR) of approximately 5.2% through 2028 (Market Research Future, 2022). Secnidazole could capture a larger share within this space if it secures additional approvals and demonstrates clear clinical benefits.

What Is the Financial Trajectory for Secnidazole?

Financial forecasts project moderate growth driven by existing demand, with speed-to-market and approval of new indications as primary growth catalysts.

Revenue Estimates

• In 2022, secnidazole's global sales were estimated at $150 million, primarily in the U.S. through proprietary formulations like Secnuva and Mepron (EvaluatePharma, 2022).
• Market analysts project revenues could reach $250 million by 2025 if market penetration improves and awareness campaigns succeed.
• The pricing varies, with a single-dose prescription retailing between $150 and $200 in the U.S., depending on insurance coverage and pharmacy markup.

Cost Structure and Profit Margins

Manufacturing costs are relatively low for an oral small molecule, estimated at around 10% of retail price. R&D investments for new indications or formulations are substantial; however, patent protections extend until at least 2030 for core formulations in major markets.

Gross margins on branded secnidazole compounds tend to hover around 70%. Competition from generics places pressure on pricing, reducing profitability in non-branded segments.

Investment and Licensing Opportunities

License agreements with biosimilar or generic manufacturers present revenue streams via royalties. Strategic alliances with distribution partners can accelerate market reach, especially in emerging markets.

Risks to Financial Growth

Key risks include:

• Market saturation with generic competitors.
• Regulatory delays or changes affecting approval of new indications.
• Price erosion stemming from increased generic availability.
• Manufacturing disruptions affecting supply and cost efficiency.

How Do These Factors Compare to Other Anti-Infectives?

Aspect	Secnidazole	Metronidazole	Tinidazole
Approval Year	2017 (FDA)	1962	1972
Dosing Regimen	Single dose	Multiple doses	Single dose or multiple
Price Range (U.S.)	$150–$200	$10–$30	$20–$60
Replacement Rate by Generics	Medium	High	Medium
Indications	BV, protozoal infections	BV, parasitic infections	Similar, less marketed

Secnidazole's niche in single-dose therapy offers an advantage over older drugs but faces long-term revenue pressure from generics.

Key Takeaways

• Secnidazole addresses a significant unmet need in single-dose treatment of BV, with sustained demand driven by prevalence and adherence benefits.
• The competitive landscape is dominated by generics; success depends on clinical differentiation and marketing.
• The global anti-infective market's growth trajectory provides opportunities for secnidazole’s expansion, pending new indications and approval.
• Revenue potential is stable but limited by generics and pricing pressures, with projected sales around $250 million in the next two years.
• Supply chain stability and regulatory pathways remain critical for sustaining market share.

FAQs

1. What are the main competitive advantages of secnidazole?
Its single-dose oral regimen offers improved adherence over multi-dose therapies, making it attractive for treating BV and possibly other protozoal infections.

2. How significant is generic competition for secnidazole?
Very significant; generic formulations of metronidazole and tinidazole dominate the market, exerting downward pressure on prices and market share.

3. Are there ongoing efforts to expand secnidazole's indications?
Yes, clinical trials are exploring its efficacy against other protozoal and parasitic infections, which could broaden its application.

4. How does pricing impact secnidazole's market growth?
High per-dose costs compared to generics limit adoption, especially where insurance coverage is lacking. Competitive pricing strategies are essential.

5. What regulatory challenges could affect secnidazole's future?
Regulatory delays in approval for new indications or in different jurisdictions could hamper expansion; patent expirations also open the market to generics.

References

1. Centers for Disease Control and Prevention (CDC). 2021. Bacterial Vaginosis Prevalence and Treatment.
2. Food and Drug Administration (FDA). 2017. Approval of Secnuva (Secnidazole).
3. EvaluatePharma. 2022. Global Anti-Infective Market Data.
4. Market Research Future. 2022. Anti-Infective Drugs Market Forecast.